公开(公告)号：US20190292568A1

公开(公告)日：2019-09-26

申请号：US16358461

申请日：2019-03-19

Applicant: Inscripta, Inc.

Inventor： Christopher Abraham ,  Charles Johnson ,  Clint Davis ,  Eileen Spindler ,  Paul Hardenbol

IPC: C12N15/90 ,  C12N15/113 ,  C12N9/22

Abstract: The present disclosure thus provides methods for higher efficiency cell editing that maintain the viability of the cells. In certain aspects, the present disclosure provides systems and instruments for automated methods of multiplexed nuclease-directed genome editing using nuclease expression under a constitutive promoter. In specific aspects, the constitutive promoter is an insulated promoter. In other aspects, the constitutive promoter is a heterologous promoter. In still other aspects, the constitutive promoter is a synthetic promoter.

公开(公告)号：US20210238535A1

公开(公告)日：2021-08-05

申请号：US17123077

申请日：2020-12-15

Applicant: Inscripta, Inc.

Inventor： Christopher Abraham

IPC: C12M1/36 ,  C12M3/00 ,  C12M1/26 ,  C12N15/90 ,  C12N9/22 ,  C12N15/11 ,  C12N5/0783

Abstract: In an illustrative embodiment, the present disclosure provides methods, systems and/or instruments for the automated editing of immune cells for chimeric antigen receptor therapies.